ocular disorder

Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.

They successfully edited the gene in mice in vivo and their approach could also work for a range of heterozygous disease-causing SNPs.

Exome sequencing poorly covers some known disease genes, but identifies novel genes that that Harvard team thinks will help improve panel's diagnostic rate.

The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.